Cost analysis of oral hypolipidemic agents available in India

Vihang S. Chawan, Kalpesh V. Gawand, Sagar V. Badwane


Background: Cardiovascular diseases are the most prevalent cause of death and disability in developed and developing countries. There is a wide variation in the prices of hypolipidemic drugs marketed in India. Thus, a study was planned to find out variation in cost in the oral hypolipidemic drugs available in India either as a single drug or in combination and to evaluate the difference in cost of various brands of the same oral hypolipidemic drug by calculating percentage variation in cost in Indian rupees.

Methods: Cost of oral hypolipidemic drugs manufactured by different pharmaceutical companies, in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” July-October 2014 and “Indian Drug Review” Vol. XXI, Issue No.4, 2014. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in cost per 10 tablets was calculated.

Results: Percentage variation in cost for hypolipidemic drugs marketed in India was found to be atorvastatin (10 mg): 1108.33%, simvastatin (5 mg): 709.09%, rosuvastatin (10 mg): 431.91%, lovastatin (10 mg): 287%, fenofibrate (200 mg): 163.58%. Among the combination therapy, variation in cost was atorvastatin + fenofibrate (10+160 mg): 233.33%, atorvastatin + ezetimibe (20+20 mg): 132.90%, rosuvastatin + fenofibrate (10+145 mg): 105.56%.

Conclusion: There is a wide difference in the cost of different brands of oral hypolipidemic drugs available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.


Hypolipidemic drugs, Variation in cost, Statins, Percentage variation

Full Text:



Sundaram VM. Pharma industry in India. Drug News Perspect. 2008;21(1):59-63.

Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35-8.

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701.

Pais P, Pogue J, Gerstein H, Zachariah E, Savitha D, Jayprakash S, et al. Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet. 1996;348(9024):358-63.

Chitra U, Reddy NK, Balakrishna N. Role of lifestyle variables on the lipid profile of selected South Indian subjects. Indian Heart J. 2012;64(1):28-34.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344(8934):1383-9.

Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9.

Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92(9):2419-25.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-7.

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-44.

Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303(6797):276-82.

Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151-67.

Keaney JF Jr, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014;370(3)275-8.

National Pharmaceutical Pricing Authority, Government of India. Available at Accessed on 04 Nov 2014.

National Pharmaceutical Pricing Authority, Government of India, Current Price list. Available at Accessed 04 Nov 2014.

National List of Essential Medicines of India. Available at,%202011.pdf. Accessed 04 Nov 2014.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.

Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. Clin Ther. 1999;21(10):1788-96.

Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis. Arq Bras Cardiol. 2001;76(5):409-18.